Halozyme Therapeutics, Inc. (HALO) on Decifer

Decifer ranks HALO number 2 of 270 tracked names on durable business quality.

Why it ranks here

• It earns strong returns on the money it puts to work, around 24% and it turns most of its profit into real cash.
• Revenue is growing about 38% a year, profits are expected to grow 22%, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• A single chokepoint for specialty biologics with returns around 24%, revenue growth of 38%, and momentum of 30 out of 35 above trend is highly investible.

The current read

The evidence on HALO lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full HALO research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.